Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA - Get Free Report) has earned an average rating of "Buy" from the ten ratings firms that are covering the firm, Marketbeat.com reports. Ten research analysts have rated the stock with a buy recommendation. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $27.89.
Several research firms recently weighed in on CNTA. Piper Sandler started coverage on shares of Centessa Pharmaceuticals in a research note on Monday, March 31st. They set an "overweight" rating and a $38.00 price objective on the stock. Wall Street Zen raised shares of Centessa Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Thursday, May 22nd. Guggenheim reaffirmed a "buy" rating and issued a $28.00 price target on shares of Centessa Pharmaceuticals in a research note on Wednesday, March 26th. Oppenheimer started coverage on shares of Centessa Pharmaceuticals in a research note on Thursday, May 8th. They issued an "outperform" rating and a $6.00 price target on the stock. Finally, Chardan Capital started coverage on shares of Centessa Pharmaceuticals in a research note on Thursday, May 8th. They issued a "buy" rating and a $30.00 price target on the stock.
Check Out Our Latest Report on CNTA
Centessa Pharmaceuticals Stock Performance
Centessa Pharmaceuticals stock traded down $0.27 during mid-day trading on Wednesday, reaching $15.69. The company had a trading volume of 1,007,312 shares, compared to its average volume of 773,725. The company has a quick ratio of 14.37, a current ratio of 14.37 and a debt-to-equity ratio of 0.28. Centessa Pharmaceuticals has a 52 week low of $9.00 and a 52 week high of $19.09. The company has a 50 day moving average of $13.24 and a 200-day moving average of $14.45. The firm has a market cap of $2.10 billion, a price-to-earnings ratio of -8.67 and a beta of 1.45.
Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) last announced its earnings results on Monday, May 12th. The company reported ($0.20) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.35) by $0.15. On average, sell-side analysts expect that Centessa Pharmaceuticals will post -1.6 EPS for the current fiscal year.
Insiders Place Their Bets
In related news, CEO Saurabh Saha sold 55,000 shares of the company's stock in a transaction dated Tuesday, May 20th. The shares were sold at an average price of $12.71, for a total transaction of $699,050.00. Following the completion of the sale, the chief executive officer owned 221,017 shares of the company's stock, valued at $2,809,126.07. This represents a 19.93% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, General Counsel Iqbal J. Hussain sold 12,000 shares of the company's stock in a transaction dated Tuesday, June 24th. The stock was sold at an average price of $14.02, for a total transaction of $168,240.00. Following the sale, the general counsel directly owned 105,386 shares of the company's stock, valued at $1,477,511.72. This represents a 10.22% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 189,398 shares of company stock valued at $2,462,692 in the last three months. Insiders own 7.09% of the company's stock.
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently made changes to their positions in the company. GF Fund Management CO. LTD. acquired a new stake in Centessa Pharmaceuticals during the 4th quarter valued at approximately $31,000. Caitong International Asset Management Co. Ltd grew its position in shares of Centessa Pharmaceuticals by 15,209.5% during the 1st quarter. Caitong International Asset Management Co. Ltd now owns 3,215 shares of the company's stock worth $46,000 after buying an additional 3,194 shares during the period. Osterweis Capital Management Inc. acquired a new stake in shares of Centessa Pharmaceuticals during the 1st quarter worth approximately $47,000. Barclays PLC grew its position in shares of Centessa Pharmaceuticals by 1,414.9% during the 4th quarter. Barclays PLC now owns 5,302 shares of the company's stock worth $89,000 after buying an additional 4,952 shares during the period. Finally, Bank of New York Mellon Corp acquired a new stake in shares of Centessa Pharmaceuticals during the 1st quarter worth approximately $147,000. Institutional investors and hedge funds own 82.01% of the company's stock.
Centessa Pharmaceuticals Company Profile
(
Get Free ReportCentessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.
Read More

Before you consider Centessa Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Centessa Pharmaceuticals wasn't on the list.
While Centessa Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.